Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigation of the Antidepressant Effects of the Selective NR2B Antagonist MK-0657 in Major Depression
Brief Summary: Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major depression.

MK-0657 decreases the activity of a brain receptor called NMDA, which the chemical glutamate binds to, possibly inducing a rapid antidepressant response. People between 18 and 55 years of age who have major depression of at least 4 weeks' duration and have not been helped by two antidepressants approved for major depression may be eligible for this study. Women who are able to have children are excluded. Participants are admitted to the NIH Clinical Center for two study phases, as follows. Phase I (1 to 2 weeks): Patients are tapered off their current medications. Phase II (7 weeks): Patients are randomly assigned to take either MK-0657 or placebo (look-alike capsules with no active ingredient) by mouth for 12 days. At some point during the second part this phase, patients who had been taking MK-0657 are switched over to placebo and those who had been taking placebo are switched to MK-0657. Participants undergo the following procedures during the study:Physical examination twice (at the beginning and at the end of the study) Electrocardiogram (ECG) four times Blood tests about six times Rating scales up to 28 times to assess the effects of MK-0657 on mood and thinking Blood pressure measurements three times a day.

Study examines the effectiveness of a new medication, targeting a system called glutamate, will improve depression when compared with placebo.


Options:
A: Arm Label: Placebo then MK-0657; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Arm Label: MK-0657 then Placebo; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Intervention Type: DRUG; Name: MK-0657; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657
B: Arm Label: Esketamine low dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - low dose | Arm Label: Esketamine medium dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - medium dose | Arm Label: Esketamine high dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - high dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo DPI | Intervention Type: DRUG; Name: Esketamine DPI - low dose; Assigned to Arm(s): Esketamine low dose | Intervention Type: DRUG; Name: Esketamine DPI - medium dose; Assigned to Arm(s): Esketamine medium dose | Intervention Type: DRUG; Name: Esketamine DPI - high dose; Assigned to Arm(s): Esketamine high dose | Intervention Type: DRUG; Name: Placebo DPI; Assigned to Arm(s): Placebo
C: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline
D: Arm Label: IV normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV normal saline | Arm Label: IV GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: SC GLYX-13; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): IV GLYX-13, SC GLYX-13 | Intervention Type: DRUG; Name: IV normal saline; Assigned to Arm(s): IV normal saline

Answer: A